|
1. |
Tamoxifen in the Prevention of Breast CancerAre the Risks Likely to Outweigh the Benefits? |
|
Drug Safety,
Volume 10,
Issue 1,
1994,
Page 1-4
Mary O'Brien,
Trevor J. Powles,
Preview
|
PDF (1749KB)
|
|
ISSN:0114-5916
出版商:ADIS
年代:1994
数据来源: ADIS
|
2. |
Safety Considerations in Assessing the Role of Immunotherapy in Allergic Disorders |
|
Drug Safety,
Volume 10,
Issue 1,
1994,
Page 5-17
Jean Bousquet,
François-B. Michel,
Preview
|
PDF (6300KB)
|
|
摘要:
Specific immunotherapy (SIT) is accepted as an effective treatment of allergic diseases when high quality extracts are used. However, this form of treatment can cause untoward reactions among which systemic reactions are the most severe. Although life-threatening reactions are rare and deaths exceptionally reported, SIT should be prescribed by allergists to patients with well defined characteristics, and administered with care by (or under the close supervision of) physicians trained to deal rapidly with the reactions. Reactions with standardised extracts occur mostly during the dose increase phase but they can be prevented using adapted schedules and premedication. During maintenance injections or when vial batches are changed, standardised extracts of known shelf-life usually result in a low rate of systemic reactions. Patients with asthma are more prone to develop systemic reactions, and allergens should not be administered to patients with a forced expiratory volume in 1 second (FEV1) under 70% of predicted or in those who have unstable or symptomatic asthma. Systemic reactions may be observed with all allergens and allergenic preparations although it appears that high molecular weight extracts may be safer.
ISSN:0114-5916
出版商:ADIS
年代:1994
数据来源: ADIS
|
3. |
Comparative Tolerability Profiles of the Newer versus Older Antidepressants |
|
Drug Safety,
Volume 10,
Issue 1,
1994,
Page 18-46
Matthew V. Rudorfer,
Husseini K. Manji,
William Z. Potter,
Preview
|
PDF (15225KB)
|
|
摘要:
Although the standard tricyclic antidepressants (TCAs) are generally effective in the treatment of depression, they can cause several troublesome adverse effects. Chief among these are their anticholinergic actions, which range from annoying dryness of the mouth and constipation to potentially dangerous urinary retention and confusion or delirium in the ill and elderly. Cardiovascular effects of TCAs include orthostatic hypotension, tachycardia and cardiac conduction slowing. Many TCAs are sedating and promote weight gain. Also problematic is the potential lethality of TCAs in overdose. The continual introduction of a host of new antidepressants over the past 15 years has provided an opportunity to improve the benefit-risk ratio for many patients by reducing medication-related toxicity. Selective serotonin reuptake inhibitors (SSRIs) and amfebutamone (bupropion), among others, are examples of effective antidepressants free of tricyclic-like anticholinergic, cardiovascular, sedating and appetite/weight-increasing effects. However, the new-generation drugs also present adverse effects of their own, including gastrointestinal distress, agitation and drug-drug interactions in the case of the SSRIs, and the risk of seizures or psychosis in amfebutamone recipients. Monoamine oxidase (MAO) inhibitors have also been refined; reversible inhibitors of MAO-type A afford protection against the usually feared hypertensive reaction to indirect sympathomimetic substances. The availability of new-generation antidepressants thus increases the likelihood of clinical response with a reduction in unwanted toxicity.
ISSN:0114-5916
出版商:ADIS
年代:1994
数据来源: ADIS
|
4. |
Adverse Effects of Drugs Used in the Management of Constipation and Diarrhoea |
|
Drug Safety,
Volume 10,
Issue 1,
1994,
Page 47-65
Jenny M. Gattuso,
Michael A. Kamm,
Preview
|
PDF (9914KB)
|
|
摘要:
Most laxatives, if used intermittently in the absence of contraindications, are relatively safe. Bulking agents may diminish absorption of some minerals and drugs, but this is not usually clinically significant. Ispaghula can cause serious allergic reactions. The chronic ingestion of stimulant laxatives has been blamed for the development of the ‘cathartic colon’, but there are no definitive studies which have demonstrated this. Dantron (danthron) preparations should only be used in older patients and the terminally ill because of the risk of hepatotoxicity with this drug. Oral oxyphenisatine should no longer be used. Senna would appear to be the stimulant laxative of choice during pregnancy and lactation. Bisacodyl is the polyphenolic derivative of choice. Lactulose, sorbitol and lactilol rarely cause significant adverse effects. Magnesium salt laxatives and phosphate enemas can cause serious metabolic disturbances in babies and young children. Liquid paraffin is contraindicated if there is any risk of aspiration. Interference with the absorption of fat soluble vitamins would not appear to be clinically significant. Docusate sodium may potentiate the hepatotoxicity of other drugs, but reports of this are rare. The role of cisapride in constipation has not been established.Antidiarrhoeal drugs are second line drugs whose use is aimed at minimising inconvenience and discomfort. No antidiarrhoeals can be recommended for children under 4 years of age. Loperamide is the drug of choice in older children and adults. The atropine component of diphenoxylate/atropine combinations can cause significant adverse effects. Bismuth salicylate is an inconvenient treatment for travellers' diarrhoea as large frequent doses of the liquid formulation are needed. Some bismuth can be absorbed and there is the potential to cause encephalopathy. Octreotide, methysergide and cholestyramine have a role for specific causes of diarrhoea only. Octreotide is effective in high output states from the small or large bowel, with few adverse effects. Clonidine and lidamidine may have a role in the treatment of chronic diabetic diarrhoea. The role of lidamidine in nondiabetic chronic diarrhoea has not been established.
ISSN:0114-5916
出版商:ADIS
年代:1994
数据来源: ADIS
|
5. |
Risk-Benefit Assessment of Omeprazole in the Treatment of Gastrointestinal Disorders |
|
Drug Safety,
Volume 10,
Issue 1,
1994,
Page 66-82
Werner Creutzfeldt,
Preview
|
PDF (9147KB)
|
|
摘要:
For the treatment of duodenal and gastric ulcer and reflux oesophagitis, especially erosive oesophagitis, omeprazole has an advantage over histamine H2-receptor antagonists because it heals significantly more patients significantly faster. Adverse effects have been observed during short term treatment with the same frequency as during treatment with H2-antagonists.Also, maintenance treatment with omeprazole of reflux oesophagitis is significantly superior to H2-antagonist therapy. During long term treatment for up to 8 years no further drug-related adverse effects have been observed. Moderate hypergastrinaemia occurs in some patients, especially if an omeprazole dosage of 40 mg/day is needed.A slight increase of the agyrophil (endocrine) cell volume density and an extension of micronodular hyperplasia in the oxyntic mucosa after several years of omeprazole treatment seem to be related to the severity of the corpus gastritis and not to drug-induced hypergastrinaemia, because similar changes have been observed in equal frequency in patients not receiving anti-secretory drugs.Theoretical arguments against long term treatment with potent acid-suppressing drugs, such as the possible consequences of gastric bacterial overgrowth or hypergastrinaemia, are not supported by clinical observations and epidemiological data and are, therefore, speculative.
ISSN:0114-5916
出版商:ADIS
年代:1994
数据来源: ADIS
|
6. |
Advances in the Critical Care of Poisoned Paediatric Patients |
|
Drug Safety,
Volume 10,
Issue 1,
1994,
Page 83-92
William Banner,
Otwell D. Timmons,
Donald D. Vernon,
Preview
|
PDF (5470KB)
|
|
摘要:
Recent improvements in paediatric intensive care may potentially improve outcome for severely poisoned children. The application of advanced techniques of critical care to the poisoned paediatric patient encompasses a wide variety of therapeutic and technical innovations that are primarily directed towards support of the cardiopulmonary system and removal of toxins. New extracorporeal removal techniques such as continuous arterio-venous haemofiltration have not substantively increased our ability to remove toxins except in rare instances. Exotic techniques such as extracorporeal membrane oxygenation remain in the background for use in rare instances only, with little clear data on the relative risks and benefits of applying them.
ISSN:0114-5916
出版商:ADIS
年代:1994
数据来源: ADIS
|
|